Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nkarta, Inc.
After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
- Gene Therapy, Cell Therapy